奈达铂联合紫杉醇脂质体或多西他赛治疗复发性卵巢癌的疗效观察

Efficacy of nedaplatin combined with paclitaxel liposome or docetaxel in the treatment of recurrent ovarian cancer

目的 探究奈达铂联合紫杉醇脂质体或多西他赛治疗复发性卵巢癌的疗效。方法 回顾性分析江苏省苏北人民医院2020年2月至2022年2月收治的85例复发性卵巢癌患者的临床资料,根据其治疗方案分为奈达铂联合紫杉醇脂质体治疗组(A组,41例)及奈达铂联合多西他赛治疗组(B组,44例)。分别记录两组铂类敏感型和铂类耐药型患者的临床疗效,比较两组患者的总体临床疗效、毒副反应及治疗前、治疗2个疗程后肿瘤标志物[糖类抗原125(CA125)、癌胚抗原(CEA)]水平;并采用Kaplan-Meier法绘制1年生存曲线,使用Logrank法比较两组患者的1年生存率差异。结果 A组铂类敏感型和铂类耐药型患者临床疗效比较,差异无统计学意义(P>0.05)。B组铂类敏感型患者临床疗效高于铂类耐药型患者(P <0.05)。两组总体临床疗效、毒副反应及1年生存率比较,差异均无统计学意义(P>0.05)。治疗2个疗程后,两组血清CA125、CEA水平均较治疗前降低(P <0.05);但两组组间比较,差异无统计学意义(P>0.05)。结论 奈达铂联合紫杉醇脂质体或联合多西他赛治疗复发性卵巢癌效果显著,铂类耐药情况对2种化疗方案影响不同,但2种化疗方案总体疗效及安全性相近,临床应用价值均较高。

Objective To explore the efficacy of nedaplatin combined with paclitaxel liposome or docetaxel in the treatment of recurrent ovarian cancer.Methods The clinical dat a of 85 patients with recurrent ovarian cancer admitted to Northern Jiangsu People's Hospital from February 2020 to February 2022 were retrospectively analyzed.According to the treatment regimens,they were divided into nedaplatin combined with paclitaxel liposome treatment group(group A,41 cases) and nedaplatin combined with docetaxel treatment group(group B,44 cases).The clinical efficacy of platinum-sensitive patients and platinum-resistant patients were recorded in the two groups.The overall clinical efficacy,toxic and side effects and tumor markers [carbohydrate antigen 125(CA125),carcinoembryonic antigen(CEA)] before treatment and after 2 courses of treatment were compared between the two groups.The 1-year survival curve was drawn by Kaplan-Meier method,and the 1-year survival rate of the two groups was compared by Log-rank method.Results There was no significant difference in the clinical efficacy between platinum-sensitive patients and platinum-resistant patients in group A(P > 0.05).The clinical efficacy of platinum-sensitive patients in group B was higher than that of platinumresistant patients(P < 0.05).There were no significant differences in the overall clinical efficacy,toxic and side effects and 1-year survival rate between the two groups(P > 0.05).After 2 treatment regimens,the serum levels of CA125 and CEA in the two groups were decreased compared with those before treatment(P < 0.05).However,there were no significant differences between the two groups(P > 0.05).Conclusions Nedaplatin combined with paclitaxel liposome or nedaplatin combined with docetaxel demonstrates significant effects in the treatment of recurrent ovarian cancer.Platinum resistance has different effects on the two chemotherapy regimens,but the two chemotherapy regimens have similar overall efficacy and safety,providing high clinical application value.